Chinese ADC Developers Forge Domestic Alliances To Push R&D

To date, nine major pairs of antibody and payload-linker platform makers based in China are making a concerted approach for ADC research and development, research by Scrip reveals.

alliance
Smaller Chinese ADC players increasingly forging partnerships based on their respective strengths • Source: Shutterstock

Since the beginning of 2023, it seems that Chinese-originated antibody-drug conjugates (ADCs) have suddenly sprinted from stealth mode into the spotlight on the global biopharma collaboration stage.

Although some domestic front-runners in the ADC field, such as RemeGen Ltd. and Kelun Biotech, have previously dominated headlines...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia